Charles River Laboratories
251 Ballardvale Street
About Charles River Laboratories
About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.
With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.
At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.
For more information, please visit www.criver.com.
Equal Employment Opportunity
Charles River Laboratories, Inc. is an Equal Opportunity Employer M/F/Disabled/Vet
448 articles about Charles River Laboratories
Charles River Laboratories Announces Second-Quarter 2020 Results
Charles River Laboratories International, Inc. reported its results for the second quarter of 2020.
Charles River Laboratories Schedules Second-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2020 financial results on Wednesday, August 5th, before the market opens.
HemaCare Adds GMPrimeTM Cryopreserved Leukopak to its GMP Product Portfolio
Simplify complex study logistics with GMP-compliant cryopreserved leukopak for the development and commercialization of cell and gene therapies
Charles River Laboratories to Participate in Jefferies and William Blair Conferences
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 nd , at 10:00 a.m. ET, and at the William Blair 40 th Annual Growth Stock Conference on Tuesday, June 9 th , at 10:00 a.m. CT (11:00 a.m. ET). Management will present an overview of Charles River’s strategic focus and business developments. A li
Charles River Laboratories Announces First-Quarter 2020 Results
Charles River Laboratories International, Inc. reported its results for the first quarter of 2020.
Charles River Laboratories Schedules First-Quarter 2020 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2020 financial results on Thursday, May 7 th , before the market opens. A conference call has been scheduled to discuss this information on Thursday, May 7 th , at 9:30 a.m. ET. Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website a
Under terms of the agreement, Charles River Laboratories will be able to provide its clients with the use of Deciphex’s flagship product.
Charles River Laboratories and Deciphex Form a Partnership to Enhance Drug Discovery & Development With Digital Pathology
Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a partnership with Deciphex, a leader in preclinical digital pathology software-as-a-service.
Charles River Laboratories To Participate In Barclays Global Healthcare Conference
Charles River Laboratories International, Inc. announced that it will participate in the Barclays Global Healthcare Conference. The Company will present on Wednesday, March 11th, at 10:15 a.m. ET.
Charles River Laboratories Adds Nancy C. Andrews, M.D., Ph.D., to Board of Directors
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of Nancy C. Andrews, M.D., Ph.D., to its Board of Directors, effective February 28, 2020.
Charles River Laboratories Schedules Fourth-Quarter 2019 Earnings and 2020 Guidance Release and Conference Call
Charles River Laboratories International, Inc. will release fourth-quarter and full-year 2019 financial results and provide 2020 guidance on Tuesday, February 11th, before the market opens.
Charles River will use its strengths to help develop potential drug candidates across Takeda’s four core therapeutic areas—oncology, gastroenterology, neuroscience and rare disease.
Charles River Laboratories to Present at the 38th Annual J.P. Morgan Healthcare Conference
Charles River Laboratories International, Inc. announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Tuesday, January 14th, at 9:30 a.m. PST, followed by a question and answer session at 10:00 a.m. PST.
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of HemaCare Corporation (OTCMKTS: HEMA) for approximately $380 million in cash, or $25.40 per HemaCare share. HemaCare will become part of Charles River’s Research Models and Services segment.
Charles River Laboratories Moves into Cell Therapies with $380 Million Acquisition of HemaCare
12/16/2019Following a partnership with Bit Bio announced earlier this month, this morning, CRL announced the acquisition of HemaCare for approximately $380 million in cash.
Charles River Announces Strategic Partnership with Bit Bio, Increasing Portfolio of Translational Drug Discovery Technologies
Partnership will leverage Bit Bio’s unique ability to generate authentic human cells at scale
Distributed Bio Launches Cosmic Antibody Library, Provides Charles River Clients Exclusive Access
Expanded antibody library expedites the drug discovery process
Charles River Laboratories Updates Tumor Model Compendium
Update adds over 100 new tumor models and 150 new bioinformatic data sets, increasing translational power of the Compendium
Charles River Laboratories to Present at Upcoming Investor Conferences
Management will present an overview of Charles River’s strategic focus and business developments.
Charles River Laboratories Announces Third-Quarter 2019 Results
Charles River Laboratories International, Inc. reported its results for the third quarter of 2019. For the quarter, revenue was $668.0 million, an increase of 14.1% from $585.3 million in the third quarter of 2018..